Diarrhea News and Research

Latest Diarrhea News and Research

Ferring reports on FDA approval of labeling supplement for EUFLEXXA to treat knee osteoarthritis

On Oct. 11, 2011, the FDA approved a labeling supplement for EUFLEXXA (1% sodium hyaluronate) that provides 26-week efficacy data from the FLEXX trial, as well as, 52-week safety data to demonstrate the safety of repeated injection cycles.

22 Oct 2011

Janssen announces FDA label update approval for PREZISTA HIV tablets

Janssen Therapeutics, Division of Janssen Products, LP, announced today that the U.S. Food and Drug Administration (FDA) has approved a label update for PREZISTA (darunavir) tablets to include 192-week data from the ARTEMIS study.

22 Oct 2011

Intestinal ecosystem more dynamic than previously thought

The intestinal ecosystem is even more dynamic than previously thought, according to two studies by UT Southwestern Medical Center researchers published in the latest issue of Science.

20 Oct 2011

ABI provides clinical update on company activities

Amarillo Biosciences, Inc. (ABI) today provided an update on company activities.

15 Oct 2011

Frozen ground tuna recalled by Osamu Corporation

Osamu Corporation of Gardena, CA is recalling up to 1,800 cases, lot# 7013, of frozen ground tuna because the FDA found decomposition in several samples of the product and also found elevated histamine levels in samples taken from one retail location.

14 Oct 2011

Cholera epidemic in Africa: Largest yet

The United Nations Children's Fund (UNICEF) has announced in a statement that the cholera epidemic in West and Central Africa is one of the worst the area has ever seen. So far this year more than 85,000 cases have been reported in the region, including 2,466 deaths.

12 Oct 2011

Walgreens Flu Impact Report

The typical flu season always coincides with the busiest travel period of the year, and last season that spelled trouble for more than 3 million U.S. vacationers whose trips were interrupted by flu-related illness, the Walgreens Flu Impact Report suggests.

12 Oct 2011

FDA approves NDA for Edgemont's Fluoxetine 60 mg tablet

Edgemont Pharmaceuticals, LLC, a neuroscience focused company, today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Fluoxetine Tablets 60 mg.

12 Oct 2011

Vertex announces availability of INCIVEK to treat hepatitis C in Canada

Vertex Pharmaceuticals Incorporated announced today that INCIVEK (telaprevir) tablets are now available in Canada for people with genotype 1 chronic hepatitis C with compensated liver disease, including cirrhosis.

11 Oct 2011

WHO facing shortage of funds as it works to scale up humanitarian response to Pakistan flooding

WHO representative Guido Sabatinelli has assured Pakistan health officials that the organization "will be scaling up its humanitarian response in all the flood-affected areas of Sindh to resolve health issues faced by the displaced people," News International reports.

11 Oct 2011

Teriflunomide drug reduces relapse rate of people with MS

A new oral drug has been shown in a large international clinical trial to significantly reduce the relapse rate of people with multiple sclerosis and to slow the progression of the disease.

7 Oct 2011

JCO publishes data from Celgene's ABRAXANE Phase II combination trial on pancreatic cancer

Celgene International Sàrl today announced that results from a clinical study of ABRAXANE in combination with gemcitabine in 67 patients with previously untreated advanced pancreatic cancer were published in an online article by the Journal of Clinical Oncology ahead of print.

7 Oct 2011

Bristol-Myers to present abstracts on research in liver disease at The Liver Meeting 2011

Bristol-Myers Squibb Company announced today that 22 abstracts on the Company's research in liver disease have been accepted for presentation at The Liver Meeting 2011, the 62nd annual meeting of the American Association for the Study of Liver Diseases, in San Francisco, November 4 - 8.

1 Oct 2011

Pfizer releases Phase III study results comparing VFEND-ERAXIS combination to VFEND for IA

Pfizer Inc. today reported the top-line results of an international Phase III clinical trial which compared the combination of VFEND (voriconazole) and ERAXISTM (anidulafungin) to VFEND monotherapy for primary therapy of invasive aspergillosis, a life-threatening invasive fungal infection that can develop as a complication in patients with compromised immune systems.

1 Oct 2011

Vertex announces abstracts from hepatitis C program to be presented at The Liver Meeting

Vertex Pharmaceuticals Incorporated today announced that abstracts from its hepatitis C program, including two late-breaking posters from studies of INCIVEK (telaprevir) tablets and VX-222, were accepted for presentation at The Liver Meeting, the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco, November 4-8, 2011.

1 Oct 2011

Food aid reaches almost half of Somalis in need but threat of disease looms, U.N. agency says

"The U.N. on Wednesday said food assistance has reached nearly half the Somalis in need, and it warned cases of diarrhea and cholera could spike with the seasonal rains expected in October," the Associated Press reports.

30 Sep 2011

Philippines health officials warn of disease risk following Typhoon Nesat

"Philippines authorities are warning of possible water-borne disease outbreaks following Typhoon Nesat," which ripped through the country on Tuesday causing widespread damage including power outages, flooding and landslides, IRIN reports (9/28). According to Reuters, at least 21 people have been killed by the storm and its consequences (Mogato, 9/28).

29 Sep 2011

Large-scale study on cat intestinal cancer could ultimately benefit humans

A recent, large-scale study on cat intestinal cancer has provided new insight into a common pet disease and its causes; the findings could ultimately benefit humans.

29 Sep 2011

Cubist plans to move CB-183,315 into Phase 3 trial for treatment of CDAD

Cubist Pharmaceuticals, Inc. today announced it plans to move CB-183,315, being studied for the treatment of a severe and sometimes life-threatening diarrhea caused by Clostridium difficile known as C. difficile-associated diarrhea, or CDAD, into late-stage trials.

29 Sep 2011

Almirall submits linaclotide MAA to EMA for treatment of IBS-C

Ironwood Pharmaceuticals, Inc. today announced that its European partner Almirall, S.A. submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for linaclotide, a guanylate cyclase type-C (GC-C) agonist, for the treatment of irritable bowel syndrome with constipation.

29 Sep 2011